Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Apr 16:5:76.
doi: 10.3389/fphar.2014.00076. eCollection 2014.

A practical approach to aid physician interpretation of clinically actionable predictive biomarker results in a multi-platform tumor profiling service

Kenneth Russell  1 , Leonid Shunyakov  2 , Karel A Dicke  3 , Todd Maney  4 , Andreas Voss  1
Affiliations

A practical approach to aid physician interpretation of clinically actionable predictive biomarker results in a multi-platform tumor profiling service

Kenneth Russell et al. Front Pharmacol. .

Abstract

Patients in whom the standard of care has failed or who have uncommon tumors for which no standard of care exists are often treated with drugs selected based on the physician's best guess. The rate of success for this method is generally low. With the advent of fast, affordable tumor profiling technologies, and a growth in the understanding of predictive biomarkers, it is now possible to identify drugs potentially associated with clinical benefit for such patients. We present the Caris approach to evidence-based tumor profiling and two patients with advanced ovarian and prostate cancer in whom standard of care had failed and tumor profiling identified an effective treatment schedule. To establish Caris Molecular Intelligence(TM) (CMI), over 120,000 clinical publications were screened and graded to characterize the predictive value of biomarkers that form the panel of tests. CMI includes multiple technologies to measure changes in proteins, ribonucleic acid, and deoxyribonucleic acid and proprietary software that matches the test results with the published evidence. The CMI results enable physicians to select drugs that are more likely to benefit the patients, avoid drugs that are not likely to work, and find treatment options that otherwise would not be considered. Worldwide, over 60,000 cancer patients have undergone evidence-based tumor profiling with CMI. In the cases reported in this article, CMI identified treatments that would not have been routinely used in the respective clinical setting. The clinical outcomes observed help to illustrate the utility of this approach.

Keywords: biomarkers; evidence-guided; oncology; personalized medicine.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Generating Molecular Intelligence: an extensive literature review is performed by a multi-disciplinary review team, which examines new research and relevant research, and grades it based on US Preventative Task Force methodology in the context of the biomarkers revealed through the profiling services. The output from this evidence review forms the basis of a proprietary software package which is used to translate the results of comprehensive biomarker testing to a clinically actionable report, providing physicians with meaningful biomarkers, actionable drug associations, and relevant clinical trials for their individual patient.
FIGURE 2
FIGURE 2
CT scans before (A,C) and 5 weeks after initiation of treatment with pemetrexed (B,D) show decrease in size of metastases and liver sclerosis and ascites due to previous embolization.
See this image and copyright information in PMC

References

    1. Bedard P. L., Ozo A. M., Tsao M. S., Leighl N. B., Shepherd F. A., Chen E. X., et al. (2013). Princess Margaret Cancer Centre integrated molecular profiling in advanced cancers trial (IMPACT) using genotyping and targeted next-generation sequencing. J. Clin. Oncol. 31(suppl.) abstr. 11002
    1. Chen C. Y., Yang P. C., Shih J. Y., Lin J. W., Chen K. Y., Yang C. H., et al. (2011). Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed. Lung Cancer 74 132–138 10.1016/j.lungcan.2011.01.024 - DOI - PubMed
    1. Dean A., Wallace R. (2013). Clinical application of molecular profiling in selecting treatment for advanced refractory and rare solid tumours: an Australian experience. Abstract 955 presented at ECCO. Available at: http://eccamsterdam2013.ecco-org.eu/Scientific-Programme/Abstract-search... (accessed April 07, 2014)
    1. Durbecq V., Paesmans M., Cardoso F., Desmedt C., Di Leo A., Chan S., et al. (2004). Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated with either single-agent doxorubicin or single-agent docetaxel. Mol. Cancer Ther. 3 1207–1214 - PubMed
    1. Harris R. P., Helfand M., Woolf S. H., Lohr K. N., Mulrow C. D., Teutsch S. M., et al. (2001). Current methods of the US Preventive Services Task Force: a review of the process. Am. J. Prev. Med. 20(3 Suppl.) 21–35 10.1016/S0749-3797(01)00261-6 - DOI - PubMed

LinkOut - more resources